Barkous Balsam, Briki Chaima, Boubakri Saba, Abdesslem Mariem, Ben Abbes Narjès, Ben Hmid Wième, Ben Saad Helmi
Farhat HACHED Hospital, Laboratory of Physiology and Functional Explorations, University of Sousse, Sousse, Tunisia.
Farhat HACHED Hospital, Heart Failure (LR12SP09) Research Laboratory, Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia.
Chron Respir Dis. 2024 Jan-Dec;21:14799731241307252. doi: 10.1177/14799731241307252.
The diagnosis and management of common chronic respiratory diseases depend on various parameters obtained from pulmonary function tests (PFTs), such as spirometry, plethysmography, and carbon monoxide diffusion capacity (DLCO). These tests are interpreted following guidelines established by reputable scientific societies like the European Respiratory Society and the American Thoracic Society (ERS/ATS). This review aimed to offer a comprehensive framework for interpreting PFTs, incorporating the latest ERS/ATS update (i.e.; 2022), and to briefly explore some complex cases to shed light on their implications for understanding PFTs. The ERS/ATS update outlines a systematic approach to interpreting PFT results, which involves several steps. Initially, results are compared to those of a healthy reference population to determine normal, low, or high parameters. Then, potential ventilatory impairments (VIs), such as obstructive or restrictive VIs, are identified, which could indicate specific chronic respiratory or extra-respiratory diseases. The severity of identified VIs or reductions in DLCO is then assessed. If bronchodilator testing is performed, its response is evaluated. Lastly, any significant changes in PFT parameters over time are noted by comparing current results with previous ones, if available. Despite the clarity provided by the ERS/ATS update, certain uncertainties persist and require clarification, such as the identification of new patterns (e.g.; non-obstructive abnormal spirometry, isolated low forced expiratory volume in 1 s), and classifications of mixed VI or lung hyperinflation in terms of functional severity. This review is a comprehensive framework for interpreting PFTs. Since some issues pose uncertainty in clinical practice, it would be beneficial to the ERS/ATS to reconcile some inconsistencies and provide clearer guidance on different classifications and VIs.
常见慢性呼吸道疾病的诊断和管理取决于从肺功能测试(PFTs)中获得的各种参数,如肺活量测定、体积描记法和一氧化碳弥散量(DLCO)。这些测试是根据欧洲呼吸学会和美国胸科学会(ERS/ATS)等知名科学协会制定的指南进行解读的。本综述旨在提供一个解读PFTs的综合框架,纳入ERS/ATS的最新更新(即2022年),并简要探讨一些复杂病例,以阐明它们对理解PFTs的意义。ERS/ATS更新概述了一种解读PFT结果的系统方法,该方法涉及几个步骤。首先,将结果与健康参考人群的结果进行比较,以确定参数正常、偏低或偏高。然后,识别潜在的通气功能障碍(VIs),如阻塞性或限制性VIs,这可能表明特定的慢性呼吸道或呼吸道外疾病。接着评估已识别的VIs的严重程度或DLCO的降低情况。如果进行了支气管扩张试验,则评估其反应。最后,如果有之前的结果,通过将当前结果与之前的结果进行比较,记录PFT参数随时间的任何显著变化。尽管ERS/ATS更新提供了清晰的指导,但仍存在一些不确定性需要澄清,例如新模式的识别(如非阻塞性异常肺活量测定、孤立的1秒用力呼气量降低),以及混合性VI或肺过度充气在功能严重程度方面的分类。本综述是一个解读PFTs的综合框架。由于一些问题在临床实践中存在不确定性,ERS/ATS协调一些不一致之处并就不同分类和VIs提供更清晰的指导将是有益的。